Biora Therapeutics, Inc. (PROG)
Price:
0.88 USD
( - -0.03 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
BioNTech SE
VALUE SCORE:
6
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Aurinia Pharmaceuticals Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
NEWS
Progenity Announces Successful Transfer of Liquid Biopsy Technologies
globenewswire.com
2022-05-05 06:30:00Enumera Molecular Formed to Develop and Commercialize Next-Generation Solutions for Liquid Biopsy Enumera Molecular Formed to Develop and Commercialize Next-Generation Solutions for Liquid Biopsy
Progenity Appoints Paul Shabram to Lead Technical Operations of the Company's Ingestible Drug/Device Platforms
globenewswire.com
2022-04-25 09:00:00Expanding Leadership Team to Accelerate Development of Innovative Therapeutic Delivery Platforms Expanding Leadership Team to Accelerate Development of Innovative Therapeutic Delivery Platforms
Progenity to Become Biora Therapeutics as it Completes Transformation
globenewswire.com
2022-04-12 09:00:00Upcoming Change Reflects the Company's Focus on Oral Delivery of Biotherapeutics Upcoming Change Reflects the Company's Focus on Oral Delivery of Biotherapeutics
Progenity Announces Two Poster Presentations at Controlled Release Society 2022
globenewswire.com
2022-04-06 09:00:00SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of two abstracts presenting preclinical data on its systemic therapeutics delivery system for presentation at the Controlled Release Society (CRS) 2022 Annual Meeting. CRS is an international gathering of experts in the design, development, and implementation of novel drug delivery technologies. This year's meeting is focused on advanced delivery science and will take place in Montreal, Canada, July 11-15, 2022.
Progenity, Inc. (PROG) CEO Adi Mohanty on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-03-28 21:41:05Progenity, Inc. (PROG) CEO Adi Mohanty on Q4 2021 Results - Earnings Call Transcript
Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
globenewswire.com
2022-03-28 16:01:00Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs
Should You Invest in These Penny Stocks Next Month? 3 to Watch
pennystocks.com
2022-03-23 13:07:08Will these penny stocks be on your watchlist in April? The post Should You Invest in These Penny Stocks Next Month?
Penny Stocks To Buy Now? 4 Short Squeeze Stocks To Watch This Week
pennystocks.com
2022-03-21 10:34:06Short squeeze stocks to watch this week. The post Penny Stocks To Buy Now?
Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update
globenewswire.com
2022-03-16 16:23:00SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern / 1:30 p.m. Pacific that day to discuss the financial results and provide a corporate update.
Progenity Progresses its Drug Delivery System Clinical Device Performance Studies
globenewswire.com
2022-03-10 09:00:00Clinical Device Performance Study in Healthy Volunteers Demonstrated Accurate Localization and Delivery
Progenity Announces Acceptance of Three Abstracts at Digestive Disease Week 2022
globenewswire.com
2022-02-28 09:00:00SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of three abstracts on the treatment of IBD and microbiome sampling for presentation at Digestive Disease Week® (DDW). DDW is the world's premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery, and will take place in person and virtually May 21-24, 2022.
Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO'22
globenewswire.com
2022-02-22 09:00:00Patient data establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting the hypotheses of targeted therapeutic delivery and potential combination therapy for ulcerative colitis Patient data establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting the hypotheses of targeted therapeutic delivery and potential combination therapy for ulcerative colitis
Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
globenewswire.com
2022-02-16 09:00:00Dr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomes Dr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomes
Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February
pennystocks.com
2022-02-14 15:18:46Here's three penny stocks that investors are watching rig The post Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top Reddit Penny Stocks That Investors Are Watching Right Now
pennystocks.com
2022-02-10 15:44:13Reddit penny stocks are heating up, here's three to know about The post Top Reddit Penny Stocks That Investors Are Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Penny Stocks Climbing During Today's Trading Session
pennystocks.com
2022-02-09 12:39:40These penny stocks climbed today, here's what you need to know The post 3 Penny Stocks Climbing During Today's Trading Session appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
No data to display
Progenity Announces Successful Transfer of Liquid Biopsy Technologies
globenewswire.com
2022-05-05 06:30:00Enumera Molecular Formed to Develop and Commercialize Next-Generation Solutions for Liquid Biopsy Enumera Molecular Formed to Develop and Commercialize Next-Generation Solutions for Liquid Biopsy
Progenity Appoints Paul Shabram to Lead Technical Operations of the Company's Ingestible Drug/Device Platforms
globenewswire.com
2022-04-25 09:00:00Expanding Leadership Team to Accelerate Development of Innovative Therapeutic Delivery Platforms Expanding Leadership Team to Accelerate Development of Innovative Therapeutic Delivery Platforms
Progenity to Become Biora Therapeutics as it Completes Transformation
globenewswire.com
2022-04-12 09:00:00Upcoming Change Reflects the Company's Focus on Oral Delivery of Biotherapeutics Upcoming Change Reflects the Company's Focus on Oral Delivery of Biotherapeutics
Progenity Announces Two Poster Presentations at Controlled Release Society 2022
globenewswire.com
2022-04-06 09:00:00SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of two abstracts presenting preclinical data on its systemic therapeutics delivery system for presentation at the Controlled Release Society (CRS) 2022 Annual Meeting. CRS is an international gathering of experts in the design, development, and implementation of novel drug delivery technologies. This year's meeting is focused on advanced delivery science and will take place in Montreal, Canada, July 11-15, 2022.
Progenity, Inc. (PROG) CEO Adi Mohanty on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-03-28 21:41:05Progenity, Inc. (PROG) CEO Adi Mohanty on Q4 2021 Results - Earnings Call Transcript
Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
globenewswire.com
2022-03-28 16:01:00Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs
Should You Invest in These Penny Stocks Next Month? 3 to Watch
pennystocks.com
2022-03-23 13:07:08Will these penny stocks be on your watchlist in April? The post Should You Invest in These Penny Stocks Next Month?
Penny Stocks To Buy Now? 4 Short Squeeze Stocks To Watch This Week
pennystocks.com
2022-03-21 10:34:06Short squeeze stocks to watch this week. The post Penny Stocks To Buy Now?
Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update
globenewswire.com
2022-03-16 16:23:00SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern / 1:30 p.m. Pacific that day to discuss the financial results and provide a corporate update.
Progenity Progresses its Drug Delivery System Clinical Device Performance Studies
globenewswire.com
2022-03-10 09:00:00Clinical Device Performance Study in Healthy Volunteers Demonstrated Accurate Localization and Delivery
Progenity Announces Acceptance of Three Abstracts at Digestive Disease Week 2022
globenewswire.com
2022-02-28 09:00:00SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of three abstracts on the treatment of IBD and microbiome sampling for presentation at Digestive Disease Week® (DDW). DDW is the world's premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery, and will take place in person and virtually May 21-24, 2022.
Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO'22
globenewswire.com
2022-02-22 09:00:00Patient data establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting the hypotheses of targeted therapeutic delivery and potential combination therapy for ulcerative colitis Patient data establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting the hypotheses of targeted therapeutic delivery and potential combination therapy for ulcerative colitis
Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
globenewswire.com
2022-02-16 09:00:00Dr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomes Dr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomes
Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February
pennystocks.com
2022-02-14 15:18:46Here's three penny stocks that investors are watching rig The post Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top Reddit Penny Stocks That Investors Are Watching Right Now
pennystocks.com
2022-02-10 15:44:13Reddit penny stocks are heating up, here's three to know about The post Top Reddit Penny Stocks That Investors Are Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Penny Stocks Climbing During Today's Trading Session
pennystocks.com
2022-02-09 12:39:40These penny stocks climbed today, here's what you need to know The post 3 Penny Stocks Climbing During Today's Trading Session appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.